A Phase 2 Multicenter, Randomized, Placebo-Controlled, Double-Blind Parallel Group Dose-Ranging Study to Evaluate the Safety and Efficacy of Topical NEOSH101 in the Treatment of Androgenetic Alopecia in Men - Alopecia

eosil Inc.0 个研究点开始时间: 2007年2月22日最近更新: 2012年3月19日

试验速览

阶段: 不适用
状态: 进行中（未招募）
发起方

研究概览入排标准研究者记录与标识符相似试验

研究概览

简要总结

暂无简介。

研究设计

研究类型: Interventional clinical trial of medicinal product

入排标准

性别: Male

入选标准

•All of the following criteria have to be met for inclusion of a subject in the study:
•Men, aged 18 to 49 years;
•written informed consent obtained;
•Norwood/Hamilton grades III - IV, androgenetic alopecia (with thinning hair in the vertex area);
•healthy skin on the scalp;
•the physical examination must be without disease findings unless the investigator considers a physical examination abnormality to be irrelevant to the outcome of the study;
•normal clinical laboratory values unless the investigator considers an abnormality to be clinically irrelevant for study participation;
•subjects either not of reproductive potential (e.g. vasectomy, documented infertility) or using adequate contraception, defined in men as a condom + spermicidal gel or foam or abstinence throughout the duration of the study.
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range
•F.1.3 Elderly (>=65 years) no
•F.1.3.1 Number of subjects for this age range

排除标准

•Subjects are to be excluded from the study when one or more of the following conditions are met:
•concomitant dermatologic or medical condition(s) which may interfere with the investigator’s ability to evaluate the subject’s response to the study drug;
•previous surgical correction of scalp hair loss;
•hair loss due to disease/drug treatment;
•subjects whose scalp is occluded regularly, eg, hair loss necessitates the wearing of a wig or hat or the subject has to wear a hat for work;
•clinically significant abnormalities in clinical chemistry, haematology or urinalysis results;
•evidence of drug or alcohol abuse;
•treatment with a systemic or locally acting medication which may interfere with the study objectives, such as minoxidil treatment in the 6 months prior to study day 1, finasteride treatment in the 12 months prior to study day 1, or treatment with other investigational hair growth products in the 6 months prior to study day 1;
•previous treatment with NEOSH101 in the 6 months prior to study day 1;
•participation in another clinical trial involving pharmaceutical products in the four weeks preceding and during the study;
•donation of blood or plasma to a blood bank or in a clinical study (excluding a screening visit) within 30 days prior study day 1 and during the study;
•major surgery within 1 month prior to study day 1;
•history of malignancy not in remission for at least 5 years excluding basal cell carcinoma and nonperiorificial squamous cell carcinoma of the skin;
•history of untreated or poorly-controlled hypertension, myocardial infarction, or other clinically significant cardiovascular disease history;
•another active intercurrent infection or any poorly controlled medical condition;
•a history of hypersensitivity or allergic reactions to propylene glycol or ethanol or to any ingredient in the vehicle-containing placebo formulation, or to hair dye used to tattoo the treatment area;
•if the subjects have a partner who is pregnant or lactating, or who intends to become pregnant during the study period;
•if the subjects are institutionalized because of legal or regulatory order;
•any reason which, in the opinion of the investigator, interferes with the ability of the subject to participate in, or complete, the trial or which places the subject at undue risk.

研究者

发起方

eosil Inc.

相似试验

进行中（未招募）

2 期

A Phase II Study of NTPI in Patients with Behavioral and Psychological Symptoms Associated with Alzheimer's Disease.

JPRN-jRCT2071220042Toyama Ikuo90

进行中（未招募）

1 期

CTIS2024-513405-31-00Celgene Corp.1

进行中（未招募）

1 期

EUCTR2014-005614-29-ESCelgene Corporation90

进行中（未招募）

不适用

EUCTR2014-005614-29-GRCelgene Corporation90

招募中

2 期

2024-513405-31-00Celgene Corp.1